Kornimate/medical-research-clean huggingface dataset:
essential oils on anxiety of patients suffering from cancer

Conditions: Neoplasm Metastasis

Summary: this study evaluates the impact of essential oils massage on anxiety of patients who are suffering from cancer at a metastasis stage. half of patients will be massaged first by essential oils and then by oil only. the other half will be massaged first by oil and then by essential oils.


Eligibility criteria:
inclusion criteria: * adult suffering from cancer at a metastatic stage * life expectancy \> 15 days, assessed by investigator * hospitalized at the chevrel unit from centre eugène marquis, palliative unit care, for more than 15 days * regular anxiolytic treatment or imperative need to introduce anxiolytic treatment (assessed by investigator) within 48 hours following his hospitalization entry * \> 18 years exclusion criteria: * patient already recruited in a therapeutic trial * patient not covered by a social security system * pregnant or likely pregnant patient, breastfeeding patient * allergy to any component of essential oils mixture and vegetable oils : bitter orange petitgrain, fine lavender, ylang-ylang, macadamia * minors, people deprived of their liberty or protected people, * impaired cognitive functions making impossible to obtain informed consent

Keywords: anxiety
anti-psychotic medication (new use) weight loss study

Conditions: Obesity

Summary: this is a pilot study to determine the safety and efficacy of an investigational product (ihbg-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain anti-psychotic medications (risperdal, seroquel, and/or zyprexa).

a total of 30 subjects will be enrolled in this study. they will be randomized in to one of two groups. one group (of 20 subjects) will take 500 mg of the investigational product (ihbg-10) 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. the other group (of 10 subjects) will take a placebo 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. subjects will take the investigational product or placebo for 12 weeks. participation in this study involves 4 study visits.

Eligibility criteria:
inclusion criteria: * men and women, age 18 and older * agree to keep diet, exercise and all current health habits stable during participation in the study * have been taking risperdal (risperidone), seroquel (quetiapine), or zyprexa (olanzapine) for less than 3 months exclusion criteria: * current active acute psychotic episode * women who are pregnant, breastfeeding or planning to become pregnant * prior bariatric surgery * use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month * obesity as a result of a clinically-diagnosed endocrine problem

Keywords: obesity weight loss weight management anti-psychotic medication nutriceutical
pet fdg assessment of change in atherosclerotic plaques after chemotherapy

Conditions: Atherosclerosis

Summary: the purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing pet fdg as part of their routine assessment.we will use pet fdg to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.


Eligibility criteria:
inclusion criteria: * women over the age of 65 diagnosed with metastatic breast cancer * men over the age of 65 diagnosed with lung cancer exclusion criteria: * patients under the age of 65 * patients diagnosed with chronic inflammatory disease or chronic infection * patients taking steroids and nsaids on a regular basis
npi-002 intravitreal implant for the delay of cataract progression

Conditions: Cataract

Summary: this study will examine the safety and efficacy npi-002 intravitreal implants post vitrectomy.


Eligibility criteria:
inclusion criteria: 1. indicated for vitrectomy 2. natural lens in place at time of vitrectomy 3. some cataract present as assessed pre-operatively exclusion criteria: 1. previous intraocular surgery in study eye. 2. clear zonular weakness or defects / coloboma. 3. not on stable dose of medications for other conditions. 4. need for oral corticosteroids during study participation. 5. evidence or history of uveitis, or ocular ischemia. 6. current smoker 7. use of supplemental oxygen 8. evidence or history of proliferative diabetic retinopathy. 9. current lung disease (pu, copd, asthma) resulting in decreased oxygen saturation. 10. sensitivity to thiol compounds. 11. participation in another clinical trial.
retro-walking versus forward-walking training using underwater treadmill in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis (Knee OA); Osteoarthritis

Summary: the purpose of this study will investigate and compare the effects of retro-walking and forward-walking underwater treadmill training on pain, function and rom in subjects with chronic knee oa

in the current study, sixty subjects from both genders, the dominant side only will be involved. they will be divided in to three equal groups: group a (experimental1), group b (experimental 2), group c (control), they will be signed a consent form to share in this study which aimed to investigate the effects of retro-walking and forward-walking underwater treadmill training on pain, function and rom in subjects with chronic knee oa

Eligibility criteria:
inclusion criteria: 1. 60 patients with chronic knee oa. 2. age ranges from 40-60 years old of both genders. 3. body mass index (bmi) 25- 35kg/m2. 4. the degree of osteoarthritis was mild or moderate and have a kellgren- lawrence radiographic grade of of1-3. 5. unilateral knee osteoarthritis involvement. exclusion criteria: 1. hydrophobia. 2. pregnancy. 3. infection. 4. psychiatric disorder. 5. haemorrhagic diathesis. 6. cardiac pacemaker. 7. all subjects with deformity of hip, knee \& ankle. 8. any cns or pns involvement. 9. recent steroidal or intraarticular injections (3 months). 10. systemic inflammatory disease and bone malignancy.

Keywords: knee osteoarthritis
efficacy of therapeutic exercise (mirror image exercise) in adolescent with chronic low back pain, through corrective of postural changes

Conditions: Low Back Pain

Summary: this study will include two groups. the study group will receive mirror-image postural exercise on the 3d postural analysis. the control group will receive a traditional exercise program.


Eligibility criteria:
inclusion criteria: * having chronic mechanical low back pain. * having a significant translational and/or rotational deformity of the lumbar spine according to the posture index scale. * having normal x-ray exclusion criteria: * severe cardiovascular disease. * previous spinal surgery. * abdominal hernia. * true leg length discrepancy. * severe respiratory disease. * pregnancy. * associated pathologies of lower limbs that may interfere with the posture such as foot, knee, and hip deformities.
treatment of incomplete abortion with 600 mcg oral misoprostol compared to standard surgical treatment

Conditions: Incomplete Abortion

Summary: this study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.


Eligibility criteria:
inclusion criteria: * past or present history of vaginal bleeding during pregnancy * open cervical os * evidence of incomplete abortion with substantial debris in the uterus (if using ultrasound) * surgical evacuation of the uterus would be advised as course of action if misoprostol was not available * generally in good health * woman lives or works within one hour of study site * woman willing to provide contact information for follow up purposes * informed consent given exclusion criteria: * contraindications to study drug * uterine size larger than 12 weeks lmp * signs of severe infection

Keywords: incomplete abortion spontaneous miscarriage
characteristics of treatment responders to galantamine

Conditions: Dementia

Summary: to investigate the characteristics of treatment responders to galantamine.

the purposes of this study are: 1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate ad for 52 weeks. 2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.

Eligibility criteria:
inclusion criteria: 1. a diagnosis of probable ad according to the criteria of the nincds-adrda 2. korean version mini-mental state examination scores between 10 and 26 3. history of cognitive decline that had been gradual in onset and progressive over at least 6 months 4. a caregiver who could assist the patient with medication, attend the assessment and provide information about the patient. exclusion criteria: 1. they had evidence of any neurodegenerative diseases other than ad (i.e. parkinson's disease, huntington's disease) 2. psychiatric disorder or severe behavioral disturbances that required psychotropic medications 3. cerebral injuries induced by trauma, hypoxia, and/or ischemia 4. clinically active cerebrovascular disease; history of seizure disorder 5. other physical conditions that required acute treatment.

Keywords: alzheimer's disease galantamine treatment response efficacy adverse event
study to determine the safety and efficacy of incb018424 in patients with polycythemia vera or essential thrombocythemia

Conditions: Myeloproliferative Neoplasm (MPN)

Summary: to evaluate the safety and efficacy profile of different treatment regimens of ruxolitinib (incb018424) administered to two groups of patients; those with polycythemia vera (pv) and those with essential thrombocythemia (et). patients in each group were refractory to hydroxyurea or for whom hydroxyurea is contraindicated.

the study consisted of a 2-stage design, which included a dose-ranging phase (during which patients received treatment at their randomized dose) and an expansion phase (after adjustment of dose/regimen to achieve an optimal balance of efficacy and safety). during the dose-ranging phase, patients in each disease group (pv or et) were randomly assigned in a 1:1:1 ratio independent of each other to receive 1 of 3 treatment regimens with ruxolitinib, 10 mg twice daily (bid), 25 mg bid, or 50 mg once daily (qd). after patients completed 2 cycles of treatment with ruxolitinib at the randomized dose, investigators were permitted to adjust the dose/regimen on an individual basis using their discretion in order to achieve an optimal balance of efficacy and safety. during the expansion phase (ie, after optimization of dose), additional patients with pv or et were enrolled to receive ruxolitinib at the dose that was selected upon review of data from the dose-ranging phase. treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of polycythemia vera or essential thrombocythemia as determined by treating physician * disease refractory to hydroxyurea or for whom treatment with hydroxyurea is contraindicated or have refused further treatment with hydroxyurea due to side effects. * patient meets baseline clinical lab parameters exclusion criteria: * treatment with interferon alpha or anagrelide within 7 days and hydroxyurea within 1 day of starting incb018424. * patients diagnosed with another malignancy unless the malignancy was cervical intraepithelial neoplasia or basal or squamous cell skin cancer and the patient has been disease free for \> 3 years * patients receiving therapy with intermediate or high dose steroids greater than the equivalent of 10 mg prednisone per day * clinically significant cardiac disease (new york heart association (nyha) class iii or iv)
gaining optimism after weight loss surgery (goals) ii

Conditions: Bariatric Surgery

Summary: this randomized controlled trial examines the feasibility, acceptability, and preliminary impact of an adapted positive psychology-motivational interviewing (pp-mi) intervention for physical activity among patients who have recently undergone bariatric surgery compared to an enhanced usual care control.

this study will test a positive psychology-motivational interviewing (pp-mi) intervention for physical activity promotion in patients who have had bariatric surgery within the past 6-12 months compared to an enhanced usual care control. the investigators will enroll and randomize 58 participants. study participation includes attending four study visits (two at baseline, one at 10 weeks, and one at 24 weeks). participants will be randomized either to a 10-week physical activity intervention that includes once-weekly phone calls, a written manual, and a fitbit activity tracker, or provision of the fitbit alone. primary outcomes include the feasibility and acceptability of the intervention. secondary outcomes include changes in physical activity and other psychological, behavioral, and physiological outcomes at 10 and 24 weeks compared to the control.

Eligibility criteria:
inclusion criteria: * adult (age 18+) * history of bariatric surgery (gastric bypass or sleeve gastrectomy) at one of two academic medical centers within the past 6-12 months * interest in increasing physical activity * low physical activity, defined as \<200 minutes/week self-reported moderate- to-vigorous physical activity * access to telephone for study sessions * able to read and speak english exclusion criteria: * cognitive deficits precluding participation or informed consent * illness likely to lead to death in the next 6 months * inability to be physically active (e.g., severe arthritis) * participation in another program targeting physical activity besides their standard offerings at the surgery center. * severe psychiatric condition limiting ability to participate (e.g., psychosis, active substance use disorder)

Keywords: positive psychology motivational interviewing physical activity
detection of cerebral proteinopathy in alzheimer's disease through magnetic resonance imaging

Conditions: Alzheimer Disease

Summary: the main goal of the t1rho/bbrc2017 study is to assess the capability of the mri sequences t1rho + multicomponent t2 relaxation analysis of detecting abnormal cerebral protein deposition in ad patients in comparison with an age-matched cognitively healthy control group. both the ad and control groups will had previously undergone amyloid pet imaging to confirm/discard cerebral proteinopathy in the context of other research studies.


Eligibility criteria:
inclusion criteria: * age ≥ 60 years * informed, written consent form * to fully satisfy the criteria for one of the two following 2 groups: 1. for the ad group: * diagnosed with ad as defined per the international working group iwg 2 criteria (fulfilling core clinical criteria plus positive core ad csf biomarkers): light to mild ad defined by mini-mental state examination (mmse) score between 15 and 27 (included). * documented positive visual read (as per ema-approved procedures for each respective tracer) of an amyloid pet scan, which in the opinion of the principal investigator is consistent with a diagnosis of ad in the last 24 months. * lumbar puncture with core ad csf biomarkers available in the last 24 months. 2. for the cognitively health group: * normal cognition as defined by the alfa study cognitive workup (molinuevo et al. 2016). confidential 17 * \[18f\]-flutemetamol pet scan performed in the context of the pet flutemetamol-fdg/bbrc2015 study in the last 24 months. * lumbar puncture with core ad csf biomarkers preferably available in the last 24 months. exclusion criteria: * past or present history of major brain disorders other than mci or ad. * contraindication to mri scanning or conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.). * participation in a clinical trial for a disease modifying drug for ad. * hypoperfusion pattern not consistent with ad diagnosis, as assessed by asl.
laparoscopic vs open pancreatectomy for body and tail pancreatic cancer

Conditions: Pancreatic Cancer; Surgery; Laparoscopy

Summary: open distal pancreatectomy (odp) has been commonly employed for the treatment of a variety of cancers in body and tail of pancreas. although many general surgical procedures have been increasingly performed laparoscopically or with laparoscopic assistance, until the current decade, laparoscopic pancreatic surgery had not been performed for its complicated anatomy. but laparoscopic distal pancreatectomy (ldp) has been widely accepted as a standard treatment for body and tail pancreatic cancer because there is no anastomosis in it, and ldp has gradually become the first choice for these cancers in clinical work. although there are several studies about the comparison between ldp and odp, most are retrospective and there is no agreement in surgical margin, lymph node numbers and prognosis to identify the oncological differences between the two surgical approaches. the investigators' pilot study showed that patients with body and tail pancreatic cancer underwent ldp had a better prognosis compared with the ones undergoing odp, with no statistics differences in postoperative complications and mortality. this perspective rct study is performed to confirm whether ldp would improve the prognosis for patients with body and tail pancreatic cancer compared with odp.


Eligibility criteria:
inclusion criteria: 1. age ≥ 19 years and ≤ 80 years, no gender limitation 2. resectable body and tail pancreatic cancer (refer to nccn 2018) 3. eastern cooperative oncology group (ecog) performance status 0-1 4. tumor locates at the body and tail of the pancreas without distant metastasis 5. no celiac trunk and superior mesenteric artery invasion 6. no operation contraindication, fit for laparoscopic surgery 7. the expected survival after surgery ≥ 3 months 8. patients who are willing and able to comply with the study procedure 9. signed informed content obtained prior to treatment exclusion criteria: 1. locally advanced unresectable body and tail pancreatic cancer 2. multi-organ and vascular resection needed 3. patients undergoing total pancreatectomy 4. benign tumor at the body and tail of the pancreas or pancreatic cancer at the head of the pancreas 5. distant metastasis or ascites detected by imaging 6. severe important organ function impairment (heart, liver, kidney) 7. patients who are with other primary malignancy or haematological disorders 8. pregnant or nursing women 9. patients who have received chemotherapy, radiotherapy and interventional therapy before the pancreatectomy 10. patients who have participated in other clinical trials for pancreatic cancer treatment within 3 months
a study to evaluate the pharmacokinetics and safety of br3409 and co-administration of br3409-1 and br3409-2 in healthy volunteers under fed conditions

Conditions: Type 2 Diabetes

Summary: the purpose of this clinical study is to evaluate the pharmacokinetics and safety of br3409 and co-administration of br3409-1 and br3409-2 in healthy volunteers under fed conditions


Eligibility criteria:
inclusion criteria: * those have body mass index (bmi: weight(kg)/the square of {height(m)}) within the range of 18.0 to 30.0 at screening visit. * for men, those who weigh 55 kg or more * for women, those who weigh 50 kg or more * those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the investigational products, expected adverse events, etc. * those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception accepted in clinical trial\*(except for hormone drugs) from the date of consent to 56 days after the last administration and disagree to provide their sperm or ovum. * methods of contraception accepted in clinical trial: combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, contraceptive diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used. exclusion criteria: * those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days before the first administration date or have taken drugs concerned about affecting this clinical trial within 10 days before the first administration date. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as interaction of investigational products, half-life of concomitant drugs, etc.) * those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months before the first day of administration. (however, the termination for participation in other clinical trials are based on the last administration date of their investigational products) * those who have a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs. (except for simple appendectomy, hernia surgery) * in the case of a female subject, those suspected pregnancy or pregnant woman, lactating woman.
biomarkers in young patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer. purpose: this research study is studying biomarkers in tissue samples from young patients with acute myeloid leukemia.

objectives: * determine the frequency of ligand-independent phosphorylation of stat3 in a small cohort of samples from pediatric patients with acute myeloid leukemia including, but not limited to, samples known to express mutated c-kit. * measure the level of stat3 phosphorylation in these samples after stimulation of three key cytokine receptors expressed on hematopoietic cells il-6r, g-csfr, and c-kit. outline: cryopreserved samples are analyzed for levels of various components of the stat3 pathway via western blotting.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia * one of the following karyotypes: * t(8;21) and wt c-kit * t(8;21) and mutant c-kit * normal karyotype patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood acute myeloid leukemia/other myeloid malignancies
national observatory of children hospitalized for bronchiolitis

Conditions: Bronchiolitis

Summary: this study is an observational, multicenter and prospective study for surveillance of case of hospitalised children for bronchiolitis associated or not to rsv or other viruses (isolated or associated with rsv)

the aim of this surveillance is to observe and describe the cases hospitalized for bronchiolitis in the 2023/2024 season in the context of routine immunization with nirsevimab.

Eligibility criteria:
inclusion criteria: * children under 12 months of age * in one of the 6 study sites * from october 15, 2023 * for acute bronchiolitis defined according to current national and international recommendations * hospitalized from the pediatric emergency department. exclusion criteria: - refusal to participate by patient relative or legal representative